Latest News and Press Releases

Cash runway now expected to extend into at least 2025 as a result of revised timeline of global Phase 3 program of CBP-201 in atopic dermatitis (AD); Longer cash runway permits continued evaluation of...

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...

SAN DIEGO and TAICANG, SUZHOU, China, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a global clinical-stage...

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB), a global clinical-stage biopharmaceutical company developing T cell-driven...

SAN DIEGO and TAICANG, China, Oct. 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Connect Biopharma Holdings Limited (Nasdaq: CNTB), please note that in...

All primary and key secondary endpoints were met and highly significant at Week 16 in 255 adult patients with moderate-to-severe ADSafety and tolerability results for CBP-201 consistent with targeting...

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,tomorrow, Tuesday, October 4 SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma...

– Company expects to report top-line data from China pivotal trial for lead drug candidate CBP-201 in atopic dermatitis in October 2022 – – Company to Host Conference Call Today at 4:30 p.m. ET – ...

Conference call and webcast to follow at 1:30 p.m. PDT/4:30 p.m. EDT SAN DIEGO and TAICANG, SUZHOU, China, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB)...

– CBP-174 in development for pruritus associated with allergic and inflammatory skin diseases, including atopic dermatitis, was observed to be safe and well-tolerated – SAN DIEGO and TAICANG, SUZHOU,...